Home
>
US Stocks
>
Accolade Inc

Accolade Inc (ACCD)

$12.48

+0.44

(+3.65%)▲

Market is closed - opens 7 PM, 02 Jun 2023

Insights on Accolade Inc

  • Increasing Revenue

    Revenue is up for the last 4 quarters, 85.52M → 99.02M (in $), with an average increase of 4.7% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 4 quarters, -342.82M → -30.43M (in $), with an average increase of 228.2% per quarter

Performance

  • $11.76
    $12.78
    $12.48
    downward going graph

    5.81%

    Downside

    Day's Volatility :8.02%

    Upside

    2.35%

    downward going graph
  • $5.24
    $17.01
    $12.48
    downward going graph

    58.01%

    Downside

    52 Weeks Volatility :69.19%

    Upside

    26.63%

    downward going graph

Returns

PeriodAccolade IncSector (Health Care)Index (Russel 2000)
3 Months
-2.82%
0.7%
-6.8%
6 Months
34.23%
-8.3%
-6.0%
1 Year
106.52%
-1.9%
-4.6%
3 Years
-59.46%
25.3%
25.9%

Highlights

Market Capitalization
866.7M
Book Value
$6.48
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-6.63
Wall Street Target Price
15.53
Profit Margin
-126.58%
Operating Margin TTM
-42.83%
Return On Assets TTM
-8.88%
Return On Equity TTM
-69.14%
Revenue TTM
363.1M
Revenue Per Share TTM
5.1
Quarterly Revenue Growth YOY
5.6000000000000005%
Gross Profit TTM
165.3M
EBITDA
-110.3M
Diluted Eps TTM
-6.63
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-6.49
EPS Estimate Next Year
-1.96
EPS Estimate Current Quarter
-0.42
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    65%Buy
    34%Hold
    0
    0%Sell
Based on 23 Wall street analysts offering stock ratings for Accolade Inc(by analysts ranked 0 to 5 stars)
Based on 23 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
15
14
13
Hold
8
8
8
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 24.44%

Current $12.48
Target $15.53

Company Financials

FY18Y/Y Change
Revenue
76.8M
-
Net Income
-61.3M
-
Net Profit Margin
-79.77%
-
FY19Y/Y Change
Revenue
94.8M
↑ 23.41%
Net Income
-56.5M
↓ 7.82%
Net Profit Margin
-59.59%
↑ 20.18%
FY20Y/Y Change
Revenue
132.5M
↑ 39.76%
Net Income
-51.4M
↓ 9.08%
Net Profit Margin
-38.76%
↑ 20.83%
FY21Y/Y Change
Revenue
170.4M
↑ 28.57%
Net Income
-50.7M
↓ 1.39%
Net Profit Margin
-29.73%
↑ 9.03%
FY22Y/Y Change
Revenue
310.0M
↑ 81.98%
Net Income
-123.1M
↑ 143.08%
Net Profit Margin
-39.71%
↓ 9.98%
FY23Y/Y Change
Revenue
363.1M
↑ 17.13%
Net Income
-459.7M
↑ 273.32%
Net Profit Margin
-126.58%
↓ 86.87%
Q4 FY21Q/Q Change
Revenue
83.5M
↑ 13.87%
Net Income
22.5M
↓ 136.08%
Net Profit Margin
26.97%
↑ 112.06%
Q1 FY22Q/Q Change
Revenue
93.8M
↑ 12.35%
Net Income
-34.6M
↓ 253.56%
Net Profit Margin
-36.86%
↓ 63.83%
Q2 FY22Q/Q Change
Revenue
85.5M
↓ 8.78%
Net Income
-342.8M
↑ 892.08%
Net Profit Margin
-400.83%
↓ 363.97%
Q3 FY22Q/Q Change
Revenue
87.6M
↑ 2.47%
Net Income
-46.5M
↓ 86.43%
Net Profit Margin
-53.08%
↑ 347.75%
Q4 FY22Q/Q Change
Revenue
90.9M
↑ 3.77%
Net Income
-39.9M
↓ 14.3%
Net Profit Margin
-43.84%
↑ 9.24%
Q1 FY23Q/Q Change
Revenue
99.0M
↑ 8.88%
Net Income
-30.4M
↓ 23.67%
Net Profit Margin
-30.73%
↑ 13.11%
FY18Y/Y Change
Total Assets
47.1M
-
Total Liabilities
230.8M
-
FY19Y/Y Change
Total Assets
65.8M
↑ 39.68%
Total Liabilities
296.4M
↑ 28.43%
FY20Y/Y Change
Total Assets
124.4M
↑ 89.19%
Total Liabilities
148.2M
↓ 50.0%
FY21Y/Y Change
Total Assets
475.5M
↑ 282.2%
Total Liabilities
84.7M
↓ 42.87%
FY22Y/Y Change
Total Assets
1.3B
↑ 170.35%
Total Liabilities
429.7M
↑ 407.59%
FY23Y/Y Change
Total Assets
903.1M
↓ 29.75%
Total Liabilities
429.3M
↓ 0.11%
Q4 FY21Q/Q Change
Total Assets
1.3B
↓ 0.51%
Total Liabilities
474.7M
↓ 11.48%
Q1 FY22Q/Q Change
Total Assets
1.3B
↑ 1.76%
Total Liabilities
429.7M
↓ 9.46%
Q2 FY22Q/Q Change
Total Assets
944.5M
↓ 26.53%
Total Liabilities
409.9M
↓ 4.6%
Q3 FY22Q/Q Change
Total Assets
931.7M
↓ 1.35%
Total Liabilities
425.4M
↑ 3.76%
Q4 FY22Q/Q Change
Total Assets
913.8M
↓ 1.92%
Total Liabilities
427.8M
↑ 0.58%
Q1 FY23Q/Q Change
Total Assets
903.1M
↓ 1.17%
Total Liabilities
429.3M
↑ 0.34%
FY18Y/Y Change
Operating Cash Flow
-38.3M
-
Investing Cash Flow
-7.2M
-
Financing Cash Flow
15.0M
-
FY19Y/Y Change
Operating Cash Flow
-16.5M
↓ 56.78%
Investing Cash Flow
-3.1M
↓ 56.41%
Financing Cash Flow
48.8M
↑ 224.71%
FY20Y/Y Change
Operating Cash Flow
-34.2M
↑ 106.96%
Investing Cash Flow
-3.5M
↑ 12.92%
Financing Cash Flow
28.2M
↓ 42.21%
FY21Y/Y Change
Operating Cash Flow
-25.2M
↓ 26.32%
Investing Cash Flow
-2.4M
↓ 31.18%
Financing Cash Flow
428.4M
↑ 1417.91%
FY22Y/Y Change
Operating Cash Flow
-62.4M
↑ 147.11%
Investing Cash Flow
-263.6M
↑ 10779.61%
Financing Cash Flow
257.9M
↓ 39.79%
FY23Y/Y Change
Operating Cash Flow
-40.7M
↓ 34.72%
Investing Cash Flow
-7.2M
↓ 97.26%
Financing Cash Flow
3.2M
↓ 98.77%
Q4 FY21Q/Q Change
Operating Cash Flow
-21.4M
↑ 94.22%
Investing Cash Flow
721.0K
↓ 98.89%
Financing Cash Flow
2.7M
↓ 41.93%
Q1 FY22Q/Q Change
Operating Cash Flow
-2.3M
↓ 89.34%
Investing Cash Flow
-532.0K
↓ 173.79%
Financing Cash Flow
2.7M
↑ 0.26%
Q2 FY22Q/Q Change
Operating Cash Flow
-30.5M
↑ 1233.67%
Investing Cash Flow
-1.3M
↑ 139.1%
Financing Cash Flow
1.5M
↓ 43.88%
Q3 FY22Q/Q Change
Operating Cash Flow
-3.0M
↓ 90.17%
Investing Cash Flow
-1.6M
↑ 28.3%
Financing Cash Flow
-370.0K
↓ 124.54%
Q4 FY22Q/Q Change
Operating Cash Flow
-35.2M
↑ 1074.51%
Investing Cash Flow
-1.9M
↑ 17.1%
Financing Cash Flow
3.1M
↓ 941.89%
Q1 FY23Q/Q Change
Operating Cash Flow
27.9M
↓ 179.37%
Investing Cash Flow
-2.4M
↑ 26.27%
Financing Cash Flow
-1.1M
↓ 134.99%

Technicals Summary

Sell

Neutral

Buy

Accolade Inc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Accolade Inc
Accolade Inc
-7.53%
34.23%
106.52%
-59.46%
-59.46%
R1 RCM Inc
R1 RCM Inc
4.57%
80.16%
-22.69%
52.87%
104.66%
10X Genomics Inc
10X Genomics Inc
0.1%
32.58%
13.7%
-35.99%
-0.55%
Veeva Systems Inc.
Veeva Systems Inc.
-7.94%
-13.44%
-1.28%
-24.32%
107.7%
GE HEALTHCARE TECHNOLOGIES INC.
GE HEALTHCARE TECHNOLOGIES INC.
-1.57%
31.44%
31.44%
31.44%
31.44%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Accolade Inc
Accolade Inc
NA
NA
NA
-6.49
-0.69
-0.09
0.0
6.48
R1 RCM Inc
R1 RCM Inc
128.18
NA
0.77
0.04
-0.06
0.04
0.0
6.5
10X Genomics Inc
10X Genomics Inc
NA
NA
NA
-1.42
-0.22
-0.11
0.0
6.91
Veeva Systems Inc.
Veeva Systems Inc.
53.48
53.48
1.27
4.18
0.15
0.07
0.0
23.48
GE HEALTHCARE TECHNOLOGIES INC.
GE HEALTHCARE TECHNOLOGIES INC.
21.01
21.01
NA
3.73
0.16
0.06
0.0
14.72
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Accolade Inc
Accolade Inc
Buy
$866.7M
-59.46%
NA
-126.58%
R1 RCM Inc
R1 RCM Inc
Buy
$6.7B
104.66%
128.18
-4.41%
10X Genomics Inc
10X Genomics Inc
Buy
$6.3B
-0.55%
NA
-32.51%
Veeva Systems Inc.
Veeva Systems Inc.
Buy
$26.2B
107.7%
53.48
22.63%
GE HEALTHCARE TECHNOLOGIES INC.
GE HEALTHCARE TECHNOLOGIES INC.
Buy
$35.4B
31.44%
21.01
9.17%

Institutional Holdings

  • ARK Investment Management LLC

    7.79%

  • BlackRock Inc

    7.15%

  • JPMorgan Chase & Co

    7.06%

  • Brown Advisory Holdings Inc

    6.98%

  • Vanguard Group Inc

    6.79%

  • Bellevue Group AG

    5.49%

Corporate Announcements

  • Accolade Inc Earnings

    Accolade Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

Accolade, Inc. of Pennsylvania provides healthcare related information for self-insured companies. The Company assists employees and their families to make healthcare decisions through its health assistants. Accolade serves customers in the United States.

Organization
Accolade Inc
Employees
2370
CEO
Mr. Rajeev Singh
Industry
Health Services

Discover More

FAQs